Moreover, the HDAC inhibitor Vorinostat is currently tested as therapeutic intervention in AD patients (https://clinicaltrials.gov/ct2/show/NCT03056495) making it an interesting target for translational research. This evidence concerns the gene HDAC9 and Alzheimer disease.